Form 4: Relay Therapeutics CFO Acquires 275,000 Stock Options

Relay Therapeutics' Chief Financial Officer, Thomas Catinazzo, was granted 275,000 stock options on January 10, 2025, which vest quarterly over four years.

Summary

• Thomas Catinazzo, the Chief Financial Officer of Relay Therapeutics, acquired 275,000 stock options on January 10, 2025.
• The exercise price of these options is $4.45 per share.
• The options vest in 16 equal quarterly installments starting after January 10, 2025, contingent on Catinazzo's continued employment with the company.
• The options expire on January 9, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There are no negative implications.

Positives

• The grant of stock options to the CFO aligns his interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the CFO.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 16 equal quarterly installments is a typical approach to incentivize long-term commitment.
• The exercise price of $4.45 is a common method of setting the price at which the options can be exercised.

Stakeholder Impact

• The stock option grant aligns the CFO's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

stock options, insider trading, executive compensation, RLAY, Relay Therapeutics, CFO, Thomas Catinazzo